NETFLIX INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that NETFLIX INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.18B | Jan 23, 2026 |
| FY2025 | Dec 31, 2024 | $39.00B | Jan 23, 2026 |
| FY2025 | Dec 31, 2023 | $33.72B | Jan 23, 2026 |
| FY2024 | Dec 31, 2022 | $31.62B | Jan 27, 2025 |
| FY2023 | Dec 31, 2021 | $29.70B | Jan 26, 2024 |
| FY2020 | Dec 31, 2020 | $6.64B | Jan 28, 2021 |
| FY2020 | Sep 30, 2020 | $6.44B | Jan 28, 2021 |
| FY2020 | Jun 30, 2020 | $6.15B | Jan 28, 2021 |
| FY2020 | Mar 31, 2020 | $5.77B | Jan 28, 2021 |
| FY2020 | Dec 31, 2019 | $5.47B | Jan 28, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $2.48B | Jan 28, 2021 |
| FY2020 | Sep 30, 2020 | $2.57B | Jan 28, 2021 |
| FY2020 | Jun 30, 2020 | $2.50B | Jan 28, 2021 |
| FY2020 | Mar 31, 2020 | $2.17B | Jan 28, 2021 |
| FY2020 | Dec 31, 2019 | $2.00B | Jan 28, 2021 |
| FY2020 | Sep 30, 2019 | $2.15B | Jan 28, 2021 |
| FY2020 | Jun 30, 2019 | $1.92B | Jan 28, 2021 |
| FY2020 | Mar 31, 2019 | $1.65B | Jan 28, 2021 |
| FY2019 | Dec 31, 2018 | $1.45B | Jan 29, 2020 |
| FY2019 | Sep 30, 2018 | $1.47B | Jan 29, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.98B | Jan 23, 2026 |
| FY2025 | Dec 31, 2024 | $8.71B | Jan 23, 2026 |
| FY2025 | Dec 31, 2023 | $5.41B | Jan 23, 2026 |
| FY2024 | Dec 31, 2022 | $4.49B | Jan 27, 2025 |
| FY2023 | Dec 31, 2021 | $5.12B | Jan 26, 2024 |
| FY2020 | Dec 31, 2020 | $542.16M | Jan 28, 2021 |
| FY2020 | Sep 30, 2020 | $789.98M | Jan 28, 2021 |
| FY2020 | Jun 30, 2020 | $720.20M | Jan 28, 2021 |
| FY2020 | Mar 31, 2020 | $709.07M | Jan 28, 2021 |
| FY2020 | Dec 31, 2019 | $586.97M | Jan 28, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.33B | Jan 23, 2026 |
| FY2025 | Dec 31, 2024 | $10.42B | Jan 23, 2026 |
| FY2025 | Dec 31, 2023 | $6.95B | Jan 23, 2026 |
| FY2024 | Dec 31, 2022 | $5.63B | Jan 27, 2025 |
| FY2023 | Dec 31, 2021 | $6.19B | Jan 26, 2024 |
| FY2022 | Dec 31, 2020 | $4.59B | Jan 26, 2023 |
| FY2021 | Dec 31, 2019 | $2.60B | Jan 27, 2022 |
| FY2020 | Dec 31, 2018 | $1.61B | Jan 28, 2021 |
| FY2018 | Sep 30, 2018 | $480.67M | Jan 29, 2019 |
| FY2018 | Jun 30, 2018 | $462.21M | Jan 29, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.39B | Jan 23, 2026 |
| FY2025 | Dec 31, 2024 | $2.93B | Jan 23, 2026 |
| FY2025 | Dec 31, 2023 | $2.68B | Jan 23, 2026 |
| FY2024 | Dec 31, 2022 | $2.71B | Jan 27, 2025 |
| FY2023 | Dec 31, 2021 | $2.27B | Jan 26, 2024 |
| FY2022 | Dec 31, 2020 | $1.83B | Jan 26, 2023 |
| FY2020 | Dec 31, 2019 | $1.67B | Jan 28, 2021 |
| FY2020 | Dec 31, 2018 | $1.22B | Jan 28, 2021 |
| FY2019 | Dec 31, 2017 | $981.00M | Jan 29, 2020 |
| FY2018 | Dec 31, 2016 | $768.00M | Jan 29, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.15B | Jan 23, 2026 |
| FY2025 | Dec 31, 2024 | $7.36B | Jan 23, 2026 |
| FY2025 | Dec 31, 2023 | $7.27B | Jan 23, 2026 |
| FY2024 | Dec 31, 2022 | $2.03B | Jan 27, 2025 |
| FY2023 | Dec 31, 2021 | $392.61M | Jan 26, 2024 |
| FY2022 | Dec 31, 2020 | $2.43B | Jan 26, 2023 |
| FY2021 | Dec 31, 2019 | ($2.89B) | Jan 27, 2022 |
| FY2020 | Dec 31, 2018 | ($2.68B) | Jan 28, 2021 |
| FY2019 | Dec 31, 2017 | ($1.79B) | Jan 29, 2020 |
| FY2018 | Dec 31, 2016 | ($1.47B) | Jan 29, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $688.22M | Jan 23, 2026 |
| FY2025 | Dec 31, 2024 | $439.54M | Jan 23, 2026 |
| FY2025 | Dec 31, 2023 | $348.55M | Jan 23, 2026 |
| FY2024 | Dec 31, 2022 | $407.73M | Jan 27, 2025 |
| FY2023 | Dec 31, 2021 | $524.59M | Jan 26, 2024 |
| FY2022 | Dec 31, 2020 | $497.92M | Jan 26, 2023 |
| FY2021 | Dec 31, 2019 | $253.04M | Jan 27, 2022 |
| FY2020 | Dec 31, 2018 | $173.95M | Jan 28, 2021 |
| FY2019 | Dec 31, 2017 | $173.30M | Jan 29, 2020 |
| FY2018 | Dec 31, 2016 | $107.65M | Jan 29, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.60B | Jan 23, 2026 |
| FY2025 | Dec 31, 2024 | $53.63B | Jan 23, 2026 |
| FY2024 | Dec 31, 2023 | $48.73B | Jan 27, 2025 |
| FY2023 | Dec 31, 2022 | $48.59B | Jan 26, 2024 |
| FY2022 | Dec 31, 2021 | $44.58B | Jan 26, 2023 |
| FY2021 | Dec 31, 2020 | $39.28B | Jan 27, 2022 |
| FY2020 | Dec 31, 2019 | $33.98B | Jan 28, 2021 |
| FY2019 | Dec 31, 2018 | $25.97B | Jan 29, 2020 |
| FY2018 | Dec 31, 2017 | $19.01B | Jan 29, 2019 |
| FY2017 | Dec 31, 2016 | $13.59B | Feb 5, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.98B | Jan 23, 2026 |
| FY2025 | Dec 31, 2024 | $28.89B | Jan 23, 2026 |
| FY2024 | Dec 31, 2023 | $28.14B | Jan 27, 2025 |
| FY2023 | Dec 31, 2022 | $27.82B | Jan 26, 2024 |
| FY2022 | Dec 31, 2021 | $28.74B | Jan 26, 2023 |
| FY2021 | Dec 31, 2020 | $28.22B | Jan 27, 2022 |
| FY2020 | Dec 31, 2019 | $26.39B | Jan 28, 2021 |
| FY2019 | Dec 31, 2018 | $20.74B | Jan 29, 2020 |
| FY2018 | Dec 31, 2017 | $15.43B | Jan 29, 2019 |
| FY2017 | Dec 31, 2016 | $10.91B | Feb 5, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.62B | Jan 23, 2026 |
| FY2025 | Dec 31, 2024 | $24.74B | Jan 23, 2026 |
| FY2025 | Dec 31, 2023 | $20.59B | Jan 23, 2026 |
| FY2025 | Dec 31, 2022 | $20.78B | Jan 23, 2026 |
| FY2024 | Dec 31, 2021 | $15.85B | Jan 27, 2025 |
| FY2023 | Dec 31, 2020 | $11.07B | Jan 26, 2024 |
| FY2022 | Dec 31, 2019 | $7.58B | Jan 26, 2023 |
| FY2021 | Dec 31, 2018 | $5.24B | Jan 27, 2022 |
| FY2020 | Dec 31, 2017 | $3.58B | Jan 28, 2021 |
| FY2019 | Dec 31, 2016 | $2.68B | Jan 29, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.28B | Jan 23, 2026 |
| FY2025 | Dec 31, 2024 | $31.30B | Jan 23, 2026 |
| FY2024 | Dec 31, 2023 | $22.59B | Jan 27, 2025 |
| FY2023 | Dec 31, 2022 | $17.18B | Jan 26, 2024 |
| FY2022 | Dec 31, 2021 | $12.69B | Jan 26, 2023 |
| FY2021 | Dec 31, 2020 | $7.57B | Jan 27, 2022 |
| FY2020 | Dec 31, 2019 | $4.81B | Jan 28, 2021 |
| FY2019 | Dec 31, 2018 | $2.94B | Jan 29, 2020 |
| FY2018 | Dec 31, 2017 | $1.73B | Jan 29, 2019 |
| FY2017 | Dec 31, 2016 | $1.13B | Feb 5, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.03B | Jan 23, 2026 |
| FY2025 | Dec 31, 2024 | $7.80B | Jan 23, 2026 |
| FY2024 | Dec 31, 2023 | $7.12B | Jan 27, 2025 |
| FY2023 | Dec 31, 2022 | $5.15B | Jan 26, 2024 |
| FY2022 | Dec 31, 2021 | $6.03B | Jan 26, 2023 |
| FY2021 | Dec 31, 2020 | $8.21B | Jan 27, 2022 |
| FY2020 | Dec 31, 2019 | $5.02B | Jan 28, 2021 |
| FY2019 | Dec 31, 2018 | $3.79B | Jan 29, 2020 |
| FY2018 | Dec 31, 2017 | $2.82B | Jan 29, 2019 |
| FY2017 | Dec 31, 2016 | $1.47B | Feb 5, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $21.86B | Jan 28, 2021 |
| FY2020 | Dec 31, 2019 | $20.72B | Jan 28, 2021 |
| FY2019 | Dec 31, 2018 | $14.87B | Jan 29, 2020 |
| FY2018 | Dec 31, 2017 | $9.05B | Jan 29, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Jan 23, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Jan 23, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Jan 23, 2026 |
| FY2024 | Dec 31, 2022 | 10 | Jan 27, 2025 |
| FY2023 | Dec 31, 2021 | 11 | Jan 26, 2024 |
| FY2020 | Dec 31, 2020 | 1 | Jan 28, 2021 |
| FY2020 | Sep 30, 2020 | 1 | Jan 28, 2021 |
| FY2020 | Jun 30, 2020 | 1 | Jan 28, 2021 |
| FY2020 | Mar 31, 2020 | 1 | Jan 28, 2021 |
| FY2020 | Dec 31, 2019 | 1 | Jan 28, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Jan 23, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Jan 23, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Jan 23, 2026 |
| FY2024 | Dec 31, 2022 | 9 | Jan 27, 2025 |
| FY2023 | Dec 31, 2021 | 11 | Jan 26, 2024 |
| FY2020 | Dec 31, 2020 | 1 | Jan 28, 2021 |
| FY2020 | Sep 30, 2020 | 1 | Jan 28, 2021 |
| FY2020 | Jun 30, 2020 | 1 | Jan 28, 2021 |
| FY2020 | Mar 31, 2020 | 1 | Jan 28, 2021 |
| FY2020 | Dec 31, 2019 | 1 | Jan 28, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4.22B | Jan 23, 2026 |
| FY2025 | Dec 31, 2024 | 4.28B | Jan 23, 2026 |
| FY2024 | Dec 31, 2023 | 432.76M | Jan 27, 2025 |
| FY2023 | Dec 31, 2022 | 445.35M | Jan 26, 2024 |
| FY2022 | Dec 31, 2021 | 443.96M | Jan 26, 2023 |
| FY2021 | Dec 31, 2020 | 442.90M | Jan 27, 2022 |
| FY2020 | Dec 31, 2019 | 438.81M | Jan 28, 2021 |
| FY2019 | Dec 31, 2018 | 436.60M | Jan 29, 2020 |
| FY2018 | Dec 31, 2017 | 433.39M | Jan 29, 2019 |
| FY2017 | Dec 31, 2016 | 430.05M | Feb 5, 2018 |